{"analyses":[{"ciLowerLimit":".72","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":".98","estimateComment":"Estimated proportion of patients with a adverse event of grade 3 or higher.","groupDescription":"Single Arm Study","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":">= grade 3 adverse event proportion","paramValue":".90","testedNonInferiority":false},{"ciLowerLimit":".66","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":".89","estimateComment":"No comparison. Estimate the proportion of patients with grade 3 or higher toxicity.","groupDescription":"Phase II toxicity","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"toxicity grade >=3 proportion","paramValue":".79","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72","upperLimit":"98","value":"90"},{"groupId":"OG001","lowerLimit":"66","upperLimit":"89","value":"79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Toxicity of CCI-779 (Temsirolimus) and bortezomib (Velcade) in patients with multiple myeloma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Toxicity of CCI779 and velcade in the phase I part of this phase I/II study. CTC criteria used.","id":"OG000","title":"CCI779 Toxicity Phase I"},{"description":"Toxicity of CCI779 and velcade in the phase II part of this phase I/II study. CTC criteria used","id":"OG001","title":"CCI779 Toxicity Phase II"}],"paramType":"NUMBER","populationDescription":"Any patient who was treated was included in the analysis.","reportingStatus":"POSTED","timeFrame":"10 months","title":"Toxicity. Number of Patients With Specific Toxicities Are Reported.","type":"PRIMARY","unitOfMeasure":"percentage of patients"}